חוב לטווח קצר להון עצמי Skye Bioscience Inc. (SKYE)

Skye Bioscience, Inc. (SKYE) develops synthetic cannabinoid-based medications, focusing on glaucoma therapy and weight management. The company relies on third-party contractors for testing and molecular synthesis, creating a vendor dependency. The business operates within an autonomous product cycle, maintaining its status as a defensive asset. As illustrated on this chart, the asset's market value is 0.00.

Developing drugs in the high-risk endocannabinoid system niche requires Skye Bioscience, Inc. (SKYE) to maintain strict liquidity control. This indicator compares liabilities with maturities of up to one year against equity, measuring the company's reliance on immediate debt financing. The price action on the short-term liabilities-to-equity chart reveals a risk of insolvency should regulatory approvals be delayed. A rising ratio signals a dangerous increase in debt service costs.